FDA — authorised 21 June 2019
- Application: NDA210557
- Marketing authorisation holder: COSETTE
- Local brand name: VYLEESI (AUTOINJECTOR)
- Indication: SOLUTION — SUBCUTANEOUS
- Status: approved
FDA authorised Vyleesi (Autoinjector) on 21 June 2019
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 21 June 2019; FDA has authorised it.
COSETTE holds the US marketing authorisation.